Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates

Journal of Chemotherapy

Volumn 19, Issue 2, 2007, Pages 172-177

  Rementeria, A ^a   Sanchez Vargas L O ^a,b   Villar, M ^a   Casals, J B ^c   Carrillo Munoz, A J ^d   Rodriguez Andres C ^a   Eraso, E ^a   Quindós, Guillermo ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE CIUDAD JUÁREZ   (Mexico)

^c Rosco Diagnostika   (Denmark)

^d Associacio Catalana d'Intelligencia Artificial   (Spain)

Author keywords

Antifungal susceptibility; Candida; Disk diffusion; M44 A; Neo Sensitabs tablets

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

AGAR GEL DIFFUSION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; FUNGUS ISOLATION; IN VITRO STUDY; NONHUMAN; TABLET; YEAST;

EID: 34247868801     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.2.172     Document Type: Article

References (23)

1. García-Ruiz JC, Amutio E, Pontón J. Invasive fungal infection in immunocompromised patients. Rev Iberoam Micol 2004; 21: 55-62.
2. Pontón J, Rüchel R, Clemonds KV, et al. Emerging pathogens. Med Mycol 2000; 38; suppl 1: 225-236.
3. Giusiano G, Mangiaterra M, Rojas F, Gámez V. Azole resistance in neonatal intensive care units. J Chemother 2005; 17: 347-350.
4. Carrillo-Muñoz AJ, Quindós G, López-Ribot JL. Current developments in antifungal agents. Curr Med Chem Anti Infect Agents 2004; 3: 297-323.
5. Odds FC. Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes? Rev Iberoam Micol 1997; 14: 83-84.
6. Espinel-Ingroff A, Warnock DW, Vazquez JA, Arthimgton-Skaggs BA. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Med Mycol 2000; 38: 293-304.
7. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-826.
8. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-247.
9. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 2004; 48: 153-160.
10. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition. NCCLS document M27-A2. 2002.
11. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, Pfaller MA, Rinaldi M, Rodriguez-Tudela JL, Verweij PE. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 3884-3889.
12. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts: approved guideline M44-A. National Committee for Clinical Laboratory Standards, Wayne, Pa., 2004.
13. Carrillo-Muñoz AJ, Cárdenes CD, Carrillo-Orive B, Rodríguez V, del Valle O, Casals J, Quindós G. Antifungal activity of voriconazole against dermatophytes and Scopulariopsis brevicaulis determined by an agar diffusion method (Neo-Sensitabs™). Rev Iberoam Micol 2005;22:108-111.
14. Rosco Diagnostica AG. Users' guide Neo-Sensitabs™ susceptibility testing. 18th edition. 2005/2006.
15. Casals JB. Tablet sensitivity testing on pathogenic fungi. J Clin Pathol 1979;32:719-722.
16. Carrillo-Muñoz AJ, Abarca L, Quindós G, et al. Multicenter evaluation of Neo-Sensitabs, a standardized diffusion method for yeast susceptibility testing. Rev Iberoam Micol 1999; 16: 97-101.
17. Carrillo-Muñoz AJ, Brió S, Alonso R, del Valle O, Santos P, Quindós G. Ciclopiroxolamine: in vitro antifungal activity against clinical yeasts isolates. Int J Antimicrob Agents 2002; 20: 375-379.
18. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-5859.
19. Testore GP, Dori L, Buonomini AR, et al. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines. Diagn Microbiol Infect Dis 2004; 50: 187-192.
20. Quindós G, Abarca L, Carrillo-Muñoz AJ, et al. Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev Iberoam Micol 1999; 16: 102-105.
21. Cantón E, Pemán J, Carrillo-Muñoz A, Orero A, Ubeda P, Viudes A, Gobernado M. Fluconazole susceptibilities of bloodstream Candida sp. isolates as determined by National Committee for Clinical Laboratory Standards method M27-A and two other methods. Clin Microbiol 1999; 37: 2197-2200.
22. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ. Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003; 41: 1875-1880.
23. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL. Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect 2005; 11: 486-492.